0
0

Chapter 25. Buspirone and Gepirone

Donald S. Robinson, M.D.; Karl Rickels, M.D.; Frank D. Yocca, Ph.D.
DOI: 10.1176/appi.books.9781585623860.428442

Sections

Excerpt

Evidence of altered central serotonergic function exists for several of the psychiatric disorders, especially the mood and anxiety disorders. Discovery of the serotonin1A (5-HT1A) receptor was instrumental in linking modulation of serotonin neurotransmission to anxiety symptoms. Similarly, the tricyclic antidepressants (TCAs) and the selective serotonin reuptake inhibitors (SSRIs) implicated serotonin in the pathophysiology and treatment of depression.

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

FIGURE 25–1. Chemical structure of buspirone.

FIGURE 25–2. Chemical structure of gepirone.

References

Albert PR, Morris SJ, Ghahremani MH, et al: A putative -helical G–coupling domain in the second intracellular loop of the 5-HT1A receptor. Ann N Y Acad Sci 861:146–161, 1998
[PubMed]
 
Alpert JE, Franznick DA, Hollander SB, et al: Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis of inpatients with major depressive disorder. J Clin Psychiatry 65:1069–1025, 2004
[PubMed]
 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 2nd Edition. Washington, DC, American Psychiatric Association, 1968
 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition. Washington, DC, American Psychiatric Association, 1980
 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition, Revised. Washington, DC, American Psychiatric Association, 1987
 
Anderson IM, Cowen PJ, Grahame-Smith DG: The effects of gepirone on neuroendocrine function and temperature in humans. Psychopharmacology 100:498–503, 1990
[PubMed]
 
Andrade R, Nicoll RA: Novel anxiolytics discriminate between postsynaptic serotonin receptors mediating different physiological responses on single neurons of the rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 336:5–10, 1987
[PubMed]
 
Arranz B, Eriksson A, Mellerup P, et al: Brain 5-HT1A and 5-HT1D and 5-HT2 receptors in suicide victims. Biol Psychiatry 35:457–463, 1994
[PubMed]
 
Azmetia EC, Gannon PJ, Kheck NM, et al: Cellular localization of the 5-HT1A receptor in primate brain neurons and glial cells. Neuropsychopharmacology 14:35–46, 1996
 
Balster RL: Preclinical studies of the abuse potential of buspirone, in Buspirone: Mechanisms and Clinical Aspects. Edited by Tunnicliff G, Eison AS, Taylor DP. New York, Academic Press, 1991, pp 97–107
 
Barrett JE, Witkin JM: Buspirone in animal models of anxiety, in Buspirone: Mechanisms and Clinical Aspects. Edited by Tunnicliff G, Eison AS, Taylor DP. New York, Academic Press, 1991, pp 37–79
 
Bielski RJ, Cunningham L, Harrigan JP, et al: Gepirone extended release in treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel group study. J Clin Psychiatry 69:571–577, 2008
[PubMed]
 
Blier P, de Montigny C: Modification of the 5HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in rat brain. Synapse 1:470–480, 1987
[PubMed]
 
Blier P, Haddjeri N, Dong J: Effect of 5-HT1A receptor agonist ORG 33062 (gepirone) and its metabolite ORG 25907 (3-OH-gepirone) on the 5-HT system in the rat brain (abstract). J Am Coll Neuropsychopharmacol Abs 140:306, 2000
 
Boehm C, Placchi M, Stallone R, et al: A double-blind comparison of buspirone, clobazam, and placebo in patients with anxiety treated in a general practice setting. J Clin Psychopharmacol 10:385–425, 1990a
 
Boehm C, Robinson DS, Gammans RE, et al: Buspirone therapy in anxious elderly patients: a controlled clinical trial. J Clin Psychopharmacology 10 (suppl):47–51, 1990b
 
Boulenger JP, Gram LF, Jolicouer FB, et al: Repeated administration of buspirone: absence of pharmacodynamic or pharmacokinetic interaction with triazolam. Hum Psychopharmacol 8:117–124, 1989
 
Brown CS, Ling FW, Farmer RG, et al: Buspirone in the treatment of premenstrual syndrome. Drug Ther Bull 8 (suppl):112–116, 1990
 
Brown TA, Barlow D: Comorbidity among anxiety disorders: implications for treatment and DSM-IV. J Consult Clin Psychol 60:835–844, 1992
[PubMed]
 
Burnet PW, Eastwood SL, Lacey K, et al: The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain. Brain Res 676:157–168, 1995
[PubMed]
 
Burnet PW, Eastwood SL, Harrison PJ: [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int 30:565–574, 1997
[PubMed]
 
Buydens-Branchey L, Branchey M, Reel-Brander C: Efficacy of buspirone in the treatment of opioid withdrawal. J Clin Psychopharmacol 25:230–236, 2005
[PubMed]
 
Cantillon M, Brunswick R, Molina D, et al: Buspirone versus haloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer's disease. Am J Geriatr Psychiatry 4:236–267, 1996
 
Chalmers DT, Watson SJ: Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain: a combined in situ hybridization/in vitro receptor autoradiographic study. Brain Res 561:51–60, 1991
[PubMed]
 
Charest A, Wainer BH, Albert PR: Cloning and differentiation-induced expression of a murine serotonin1A receptor in a septal cell line. J Neurosci 13:5164–5171, 1993
[PubMed]
 
Charney DS, Heninger GR: Noradrenergic function and the mechanism of action of antianxiety treatment, I: the effect of long-term alprazolam treatment. Arch Gen Psychiatry 42:458–467, 1985
[PubMed]
 
Cheetham SC, Crompton MR, Katona CL, et al: Brain 5-HT-1 binding sites in depressed suicides. Psychopharmacol 102:544–548, 1990
[PubMed]
 
Cinciripini PM, Lapitsky L, Seay S, et al: A placebo-controlled evaluation of the effects of buspirone on smoking cessation: differences between high- and low-anxiety smokers. J Clin Psychopharmacol 15:182–191, 1995
[PubMed]
 
Ciraulo DA, Shader RL: Question the experts: safety of buspirone with an MAOI. J Clin Psychopharmacol 10:306, 1990
 
Cowen PJ, Anderson IM, Grahame-Smith DG: Neuroendocrine effects of azapirones. J Clin Psychopharmacol 10 (suppl):21S–25S, 1990
 
Cullen WK, Rowan MJ: Gepirone and 1-(2-pyrimidinyl)-piperazine-induced reduction of aversively evoked ultrasonic vocalization in the rat. Pharmacol Biochem Behav 48:301–306, 1994
[PubMed]
 
Davidson JRT, DuPont RL, Hedges D, et al: Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 60:528–535, 1999
[PubMed]
 
De Vivo M, Maayani S: Characterization of the 5-hydroxytryptamine1A receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea pig and rat hippocampal membranes. J Pharmacol Exp Ther 238:248–253, 1986
 
del Olmo E, Lopez-Gimenez JF, Vilaro MT, et al: Early localization of mRNA coding for 5-HT1A receptors in human brain during development. Mol Brain Res 60:123–126, 1998
 
DeMartinis N, Rynn M, Rickels K, et al: Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder. J Clin Psychiatry 61:91–94, 2000
[PubMed]
 
Derogatis LR: The Derogatis Interview for Sexual Functioning (DISF/DISF-SR): an introductory report. J Sex Marital Ther 23:291–304, 1997
[PubMed]
 
Detke MJ, Rickels M, Lucki I: Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 121:66–72, 1995
[PubMed]
 
Dimitriou EC, Dimitriou CE: Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol 18:465–469, 1998
[PubMed]
 
Dockens RC, Salazar DE, Fulmor E, et al: Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic range. J Clin Pharmacol 46:1308–1312, 2006
[PubMed]
 
Duman RS, Nakagawa S, Malberg J: Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology 25:836–844, 2001
[PubMed]
 
Eison AS, Eison MS: Serotonergic mechanisms in anxiety. Prog Neuropsychopharmacol Biol Psychiatry 18:47–62, 1994
[PubMed]
 
Eison AS, Temple DL: Buspirone: review of its pharmacology and current perspectives on its mechanism of action. Am J Med 80:1–9, 1986
[PubMed]
 
Eison AS, Yocca FD, Taylor DP: Mechanism of action of buspirone: current perspectives, in Buspirone: Mechanisms and Clinical Aspects. Edited by Tunnicliff G, Eison AS, Taylor DP. New York, Academic Press, 1991, pp 3–17
 
El Mestikawy S, Riad M, Laport AM: Production of specific anti-rat 5-HT1A receptor antibodies in rabbits injected with a synthetic peptide. Neurosci Lett 118:189–192, 1990
 
Enkelmann R: Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology 105:428–432, 1991
[PubMed]
 
Fargin A, Raymond JR, Lohse MJ, et al: The genomic clone G-21 which resembles a -adrenergic receptor sequence encodes the 5-HT1A receptor. Nature 335:358–360, 1988
[PubMed]
 
Feiger A: A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. Psychopharmacology Bull 32:659–665, 1996
[PubMed]
 
Feiger AD, Heiser JF, Smith WT, et al: Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry 64:243–249, 2003
[PubMed]
 
Feighner JP, Merideth CH, Hendrickson GA: A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J Clin Psychiatry 43:103–107, 1982
[PubMed]
 
Fitton A, Benfield P: Gepirone in depression and anxiety disorders. CNS Drugs 1:388–398, 1994
 
Fletcher A, Forster EA, Bill DJ, et al: Electrophysiology, biochemical, neurohormonal and behavioral studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav Brain Res 73:337–353, 1996
[PubMed]
 
Fontaine R, Chouinard G, Annable L: Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment. Am J Psychiatry 141:848–852, 1984
[PubMed]
 
Gammans RE, Johnston RE: Metabolism, pharmacokinetics, and toxicology of buspirone, in Buspirone: Mechanisms and Clinical Aspects. Edited by Tunnicliff G, Eison AS, Taylor DP. New York, Academic Press, 1991, pp 233–260
 
Gammans RE, Westrick ML, Shea JP, et al: Pharmacokinetics of buspirone in elderly subjects. J Clin Pharmacol 29:72–78, 1989
[PubMed]
 
Gilbert F, Dourish CT, Brazell C: Relationship of increased food intake and plasma ACTH levels to 5-HT1A receptor activation in rats. Psychoneuroendocrinology 13:471–478, 1988
[PubMed]
 
Giral P, Martin P, Soubrie P, et al: Reversal of helpless behavior in rats by putative 5-HT-1(a) agonists. Biol Psychiatry 23:237–242, 1988
[PubMed]
 
Glaser HL, Traber J: Buspirone: action on serotonergic receptors in calf hippocampus. Eur J Pharmacol 88:137–138, 1983
[PubMed]
 
Goldberg HL, Finnerty R: The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatry 136:1184–1187, 1979
[PubMed]
 
Goldberg HL, Finnerty R: Comparison of buspirone in two separate studies. J Clin Psychiatry 43:87–91, 1982
[PubMed]
 
Gonul AS, Oguz A, Yabanoglu I, et al: Buspirone and pindolol in augmentation therapy of treatment-resistant depression. Eur J Neuropsychopharmacology 9 (suppl):S215, 1999
 
Greenblatt DJ, Harmatz JS, Gouthro TA, et al: Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic studies. Clin Pharmacol Ther 56:100–111, 1994
[PubMed]
 
Gross C, Zhuang X, Stark K, et al: Serotonin1A receptor acts during development to establish normal anxiety-like behavior in the adult. Nature 416:396–400, 2002
[PubMed]
 
Hamilton M: The assessment of anxiety states by rating. J Med Psychol 32:50–55, 1959
[PubMed]
 
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62, 1960
[PubMed]
 
Hamon M, Bourgoin S, Gozlan H, et al: Biochemical evidence for the 5-HT agonist properties of PAT (8-hydroxy-2-(di-n-propylamino)tetralin) in the rat brain. Eur J Pharmacol 100:263–276, 1984
[PubMed]
 
Hilleman DE, Mohiuddin SM, Del Core MG, et al: Effect of buspirone on withdrawal symptoms associated with smoking cessation. Arch Gen Psychiatry 152:73–77, 1992
 
Hoyer D, Hannon JP, Martin GR: Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71:533–554, 2002
[PubMed]
 
Jacobsen FM: Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 52:217–220, 1991
[PubMed]
 
Jenkins SW, Robinson DS, Fabre LF, et al: Gepirone in the treatment of major depression. J Clin Psychopharmacol 10 (suppl): 77S–85S, 1990
 
Kehne JH, Cassella JV, Davis M: Anxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm. Psychopharmacology 94:8–13, 1988
[PubMed]
 
Keller MB, Ruwe FJJ, Janssens CJJG, et al: Relapse prevention with gepirone ER in outpatients with major depression. J Clin Psychopharmacol 25:79–84, 2005
[PubMed]
 
Kendler KS, Nearle MC, Kessler RC, et al: Major depression and generalized anxiety disorder: same genes, (partly) different environments? Arch Gen Psychiatry 49:716–722, 1992
[PubMed]
 
Kobilka BK, Frielle T, Collins S, et al: An intronless gene encoding a potential member of the family of receptors coupled to guanine nucleotide regulatory proteins. Nature 329:75–79, 1987
[PubMed]
 
Laakman G, Schule C, Lorkowski G, et al: Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology 136:357–366, 1998
 
Lader M, Scotto JC: A multicenter double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology 139:402–406, 1998
[PubMed]
 
Landren M, Bjorling G, Agren H, et al: A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 59:664–668, 1998
 
Lee ST, Park JH, Kim M: Efficacy of the 5-HT1A agonist, buspirone hydrochloride, in migraineurs with anxiety: a randomized, prospective, parallel group, double-blind, placebo-controlled study. Headache 45:1004–1011, 2005
[PubMed]
 
Lesch KP: The ipsapirone/5-HT1A receptor challenge in anxiety disorders and depression, in Serotonin 1A Receptors in Depression and Anxiety. Edited by Stahl S, Gastpar M, Keppel Hesselink JM, et al. New York, Raven, 1992, pp 387–407
 
Lucki I, Rickels K, Giesecke A, et al: Differential effects of the anxiolytic drugs, diazepam and buspirone on memory function. Br J Clin Pharmacol 23:207–211, 1987
[PubMed]
 
Martin P, Beninger RJ, Hamon M, et al: Antidepressant-like action of 8-OH-DPAT, a 5-HT1A agonist, in the learned helplessness paradigm: evidence for a postsynaptic mechanism. Behav Brain Res 38:135–144, 1990
[PubMed]
 
Matsubara S, Arora RC, Meltzer HY: Serotonergic measures in suicide brain: 5-HT1A binding sites in the frontal cortex of suicide victims. J Neural Transm 85:181–194, 1991
[PubMed]
 
Mattila MJ, Aranko K, Seppala T: Acute effects of buspirone and alcohol on psychomotor skills. J Clin Psychiatry 43:56–60, 1982
[PubMed]
 
McGrath PJ, Stewart JW, Quitkin FM, et al: Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement. J Clin Psychopharmacol 14:347–352, 1994
[PubMed]
 
Meller E, Goldstein M, Bohmaker K: Receptor reserve for 5-hydroxtryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to the anxiolytic properties of 5-hydroxytryptamine1A agonists. Mol Pharmacol 37:231–237, 1990
[PubMed]
 
Meltzer HY, Fleming R: Effect of buspirone on prolactin and growth hormone secretion in laboratory rodents and man. J Clin Psychiatry 43:76–80, 1982
[PubMed]
 
Meltzer HY, Gudelsky GA, Lowy MT, et al: Neuroendocrine effects of buspirone: mediation by dopaminergic and serotonergic mechanisms, in Buspirone: Mechanisms and Clinical Aspects. Edited by Tunnicliff G, Eison AS, Taylor DP. New York, Academic Press, 1991, pp 177–192
 
Mennini T, Gobbi M, Ponzio F, et al: Neurochemical effects of buspirone in rat hippocampus: evidence for selective activation of 5HT neurons. Arch Int Pharmacodyn Ther 279:40–49, 1986
[PubMed]
 
Mennini T, Caccia C, Garattini S: Mechanism of action of anxiolytic drugs. Prog Drug Res 31:315–347, 1987
[PubMed]
 
Murphy SM, Owen R, Tyrer P: Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks' treatment with diazepam or buspirone. Br J Psychiatry 154:529–534, 1989
[PubMed]
 
New JS: The discovery and development of buspirone: a new approach to the treatment of anxiety. Med Res Rev 3:283–326, 1990
 
Newton RE, Maruncyz JD, Alderdice MT, et al: Review of the side effect profile of buspirone. Am J Med 80 (suppl):17–21, 1986
 
Noyes R, Garvey MJ, Cooke BL, et al: Benzodiazepine withdrawal: a review of the evidence. J Clin Psychiatry 49:383–389, 1988
 
Palacios JM, Waeber C, Hoyer D, et al: Distribution of serotonin receptors. Ann N Y Acad Sci 600:36–52, 1990
[PubMed]
 
Pan LH, Gilbert F: Activation of 5-HT1A receptor subtype in the paraventricular nuclei of the hypothalamus induces CRH and ACTH release in the rat. Neuroendocrinology 56:797–802, 1992
[PubMed]
 
Parks CL, Robinson PS, Sibille E, et al: Increased anxiety of mice lacking the serotonin1A receptor. Proc Natl Acad Sci U S A 95:10734–10739, 1998
[PubMed]
 
Pattij T, Groenick L, Hijzen TH, et al: Autonomic changes associated with enhanced anxiety in 5-HT1A receptor knockout mice. Neuropsychopharmacology 27:380–390, 2002
[PubMed]
 
Pecknold JC, Matas M, Howarth BG, et al: Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo. Am J Psychiatry 34:766–771, 1989
[PubMed]
 
Pierce KL, Premont RT, Lefkowitz RJ: Seven-transmembrane receptors. Nat Rev Mol Cell Biol 3:639–650, 2002
[PubMed]
 
Pohl R, Balon R, Yeragani VK, et al: Serotonergic anxiolytics in the treatment of panic disorders: a controlled study with buspirone. Psychopathology 22 (suppl):60–67, 1989
 
Rausch JL, Stall SM, Hauger RL: Cortisol and growth hormone responses to the 5-HT1A agonist gepirone in depressed patients. Biol Psychiatry 28:73–78, 1990
[PubMed]
 
Riad M, Garcia S, Watkins KC, et al: Somatodendritic localization of 5-HT1A and pre-terminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J Comp Neurol 417:181–194, 2000
[PubMed]
 
Riblet LA, Taylor DP, Eison MS, et al: Pharmacology and neurochemistry of buspirone. J Clin Psychiatry 43:81–86, 1982
 
Rickels K: Buspirone in clinical practice. J Clin Psychiatry 51 (suppl):51–54, 1990
 
Rickels K, Schweizer E: The clinical course and long-term management of generalized anxiety disorder. J Clin Psychopharmacol 19:101S–105S, 1990
 
Rickels K, Weisman K, Norstad M, et al: Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 43:81–86, 1982
[PubMed]
 
Rickels K, Schweizer E, Csanalosi I, et al: Long-term treatment of anxiety and risk of withdrawal. Arch Gen Psychiatry 45:444–450, 1988
[PubMed]
 
Rickels K, Freeman E, Sondheimer S: Buspirone in treatment of premenstrual syndrome. Lancet 1(8641):777, 1989
[PubMed]
 
Rickels K, Amsterdam JD, Clary C, et al: Buspirone in major depression: a controlled study. J Clin Psychiatry 52:34–38, 1991
[PubMed]
 
Rickels K, Downing R, Schweizer E, et al: Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 50:884–895, 1993
[PubMed]
 
Rickels K, Schweizer E, DeMartinis N, et al: Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. J Clin Psychiatry 17:272–277, 1997
[PubMed]
 
Rickels K, Khalid-Kahn S, Rynn M: Buspirone in the treatment of anxiety disorders, in Anxiety Disorders. Edited by Nutt DJ, Ballenger JC. Oxford, England, Blackwell Publishing, 2003, pp 381–397
 
Ritchie LD, Cox J: A multicenter study of buspirone in the treatment of anxiety disorders in the elderly. Br J Clin Res 4:131–139, 1993
 
Robinson DS: Buspirone in the treatment of anxiety, in Buspirone: Mechanisms and Clinical Aspects. Edited by Tunnicliff G, Eison AS, Taylor DP. New York, Academic Press, 1991, pp 3–17
 
Robinson DS, Khan A: Dosing strategies for antidepressant clinical trials: a commentary. J Clin Psychopharmacol 24:1–3, 2004
[PubMed]
 
Robinson DS, Napoliello MJ, Schenk J: The safety and usefulness of buspirone as an anxiolytic drug in elderly versus young patients. Clin Ther 10:740–746, 1988
[PubMed]
 
Robinson DS, Alms DR, Shrotriya RC, et al: Serotonergic anxiolytics and treatment of depression. Psychopathology 22 (suppl):27–36, 1989a
 
Robinson DS, Shrotriya RC, Alms KR, et al: Treatment of panic disorder: nonbenzodiazepine anxiolytics, including buspirone. Psychopharmacol Bull 25:21–26, 1989b
 
Robinson DS, Rickels K, Feighner J, et al: Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 10:67S–76S, 1990
 
Sathananthan GL, Sanghvi I, Phillips N, et al: Correlation between neuroleptic potential and stereotypy. Curr Ther Res 18:701–705, 1975
[PubMed]
 
Scheibe G: Four-year follow-up in 40 outpatients with anxiety disorders: buspirone versus lorazepam. Eur J Psychiatry 10:25–34, 1996
 
Schweizer E, Rickels K: Failure of buspirone to manage benzodiazepine withdrawal. Am J Psychiatry 143:12, 1986
 
Schweizer E, Rickels K, Hassman, et al: Buspirone and imipramine for the treatment of major depression in the elderly. J Clin Psychiatry 59:175–183, 1998
[PubMed]
 
Sharp T, Bramwell SR, Grahame-Smith DG: 5-HT1A agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol 96:283–290, 1989
[PubMed]
 
Sheehan DV, Raj AB, Harnett-Sheehan K, et al: Is buspirone effective in panic disorder? J Clin Psychopharmacol 10:3–11, 1990
[PubMed]
 
Shiaie RD, Pancheri P, Casacchia M, et al: Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study. J Clin Psychopharmacol 15:12–19, 1995
 
Skolnick P, Weissman BA, Youdim MBH: Monoaminergic involvement in the pharmacologic actions of buspirone. Br J Pharmacol 86:637–644, 1985
[PubMed]
 
Smiley A: Effects of minor tranquilizers and antidepressants on psychomotor performance. J Clin Psychiatry 49 (suppl):22–28, 1987
 
Smiley A, Moskowitz H: The effect of chronically administered buspirone and diazepam on driver steering control. Am J Med 80:22–29, 1986
[PubMed]
 
Stahl SM: Serotonin receptors and the mechanism of action of antidepressant drugs: postmortem, platelet, and neuroendocrine studies in depressed patients, in Serotonin 1A Receptors in Depression and Anxiety. Edited by Stahl S, Gastpar M, Keppel Hesselink JM, et al. New York, Raven, 1992, pp 135–162
 
Stefanski R, Palejko W, Kostowski W: The comparison of benzodiazepine derivatives and serotonergic agonist and antagonists in two animal models of anxiety. Neuropharmacology 31:1251–1258, 1992
[PubMed]
 
Stockmeier CA, Shapiro LA, Dilley GE, et al: Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression: postmortem evidence for decreased serotonin activity. J Neurosci 18:7394–7401, 1998
[PubMed]
 
Sussman N, Chow JCY: Current issues in benzodiazepine use of anxiety disorders. Psychiatr Ann 18:139–145, 1988
 
Tay LK, Sciacca MA, Sostrin MB, et al: Effect of food on the bioavailability of gepirone in humans. J Clin Pharmacol 33:631–635, 1993
[PubMed]
 
Timmer CJ, Sitsen JMA: Pharmacokinetic evaluation of gepirone immediate-release capsules and gepirone extended-release tablets in healthy volunteers. J Pharmaceutical Sci 92:1773–1778, 2003
[PubMed]
 
Tomatzky W, Miczek KA: Alcohol, anxiolytics and the social stress test. Psychopharmacol 121:66–72, 1995
 
Tompkins EC, Clemento AJ, Taylor DP, et al: Inhibition of aggressive behavior in rhesus monkeys by buspirone. Res Commun Psychol Psychiatr Res 5:337–352, 1980
 
Trivedi M, Fava M, Wiesnewski SR, et al: Medication augmentation after failure of SSRIs for depression. N Engl J Med 354:1243–1252, 2006
[PubMed]
 
Udelman HD, Udelman DL: Concurrent use of buspirone in anxious patients during withdrawal from alprazolam therapy. J Clin Psychiatry 51 (suppl):91–96, 1990
 
Van de Kar LD, Karteszi M, Bethea CL, et al: Serotonergic stimulation of prolactin and corticosterone secretion is mediated by different pathways from the mediobasal hypothalamus. Neuroendocrinology 41:380–384, 1985
 
Vicentic A, Li Q, Battaglia G, et al: WAY-100635 inhibits 8-OH-DPAT-stimulated oxytocin, ACTH and corticosterone, but not prolactin secretion. Eur J Pharmacol 346:261–266, 1998
[PubMed]
 
Ward NM, Drinkenburg WH, Shahid M: The preclinical antidepressant profile of the 5-HT1A receptor agonist ORG 33062 (gepirone) and its metabolite ORG 25907 (3-OH-gepirone) (abstract). J Am Coll Neuropsychopharmacol Abs 59:264, 2000
 
West R, Hajek P, McNeill A: Effect of buspirone on cigarette withdrawal symptoms and short-term abstinence rates in a smokers' clinic. Psychopharmacology 104:91–96, 1991
[PubMed]
 
Wieland S, Lucki I: Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test. Psychopharmacology 101:497–504, 1990
[PubMed]
 
Wilcox CS, Ferguson JM, Dale JL, et al: A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. Psychopharmacol Bull 32:335–342, 1996
[PubMed]
 
Wise CD, Berger BD, Stein L: Benzodiazepines: anxiety reducing activity by reduction of serotonin turnover in the brain. Science 177:180–183, 1972
[PubMed]
 
Wong H, Dockens RA, Pajor L, et al: 6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. Drug Metab Dispos 35:1387–1392, 2007
[PubMed]
 
Wray NR, James MR, Mah SP, et al: Anxiety and comorbid measures associated with PLXNA2. Arch Gen Psychiatry 64:318–3236, 2007
[PubMed]
 
Wu YH, Smith KR, Rayburn JW, et al: Psychosedative agents: N (4-phenyl-1-piperazinylalkyl)-substituted cyclic imides. J Med Chem 12:876–881, 1969
[PubMed]
 
Yocca FD: Neurochemistry and neurophysiology of buspirone and gepirone: interactions at presynaptic and postsynaptic 5-HT1A receptors. J Clin Psychiatry 10:6S–12S, 1990
 
Yocca F, Altar CA: Partial agonism of dopamine, serotonin and opiate receptors in psychiatry. Drug Discovery Today: Therapeutic Strategies 3:429–435, 2006
 
Yocca FD, Eison AS, Hyslop DK, et al: Unique modulation of central 5-HT-2 binding sites and 5-HT-2 receptor mediated behavior by continuous gepirone treatment. Life Sci 49:1777–1785, 1991
[PubMed]
 
Yocca FD, Iben L, Meller E: Lack of apparent receptor reserve at postsynaptic 5-HT1A receptors negatively coupled to adenylyl cyclase activity in rat hippocampal membranes. Mol Pharmacol 41:1066–1072, 1992
[PubMed]
 
Zhu M, Zhao W, Jimenez H, et al: Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos 33:500–507, 2005
[PubMed]
 
+

CME Activity

Add a subscription to complete this activity and earn CME credit.
Sample questions:
1.
Which of the following is descriptive of buspirone’s pharmacological profile?
2.
Which of the following statements concerning buspirone’s pharmacokinetic profile is true?
3.
You are considering switching your patient, who has been taking a benzodiazepine for 2 years for generalized anxiety disorder (GAD), to buspirone. Which of the following describes an important study finding directly relevant to this decision?
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
Helping Parents, Youth, and Teachers Understand Medications for Behavioral and Emotional Problems: A Resource Book of Medication Information Handouts, 3rd Edition > Chapter 8.  >
Dulcan's Textbook of Child and Adolescent Psychiatry > Chapter 50.  >
What Your Patients Need to Know About Psychiatric Medications, 2nd Edition > Chapter 9.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 12.  >
Topic Collections
Psychiatric News
PubMed Articles
Dopamine D3 receptor ligands for drug addiction treatment: update on recent findings. Prog Brain Res 2014;211():255-75.doi:10.1016/B978-0-444-63425-2.00011-8.
Psychiatric agents and implications for perioperative analgesia. Best Pract Res Clin Anaesthesiol 2014;28(2):167-181.doi:10.1016/j.bpa.2014.05.001.
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation